1. Poletti S, Aggio V, Hoogenboezem T, Ambree O, de Wit H, Wijkhuijs A, et al. Brain-derived neurotrophic factor (BDNF) and gray matter volume in bipolar disorder. Eur Psychiatry 2017; 40:33-37.
2. Thomas T, Stansifer L, Findling RL. Psychopharmacology of pediatric bipolar disorders in children and adolescents. Pediatr Clin North Am 2011; 58:173-187.
3. Harvey PD, Wingo AP, Burdick KE, Baldessarini RJ. Cognition and disability in bipolar disorder: lessons from schizophrenia research. Bipolar Disord 2010; 12:364-375.
4. Baldez DP, Biazus TB, Rabelo-da-Ponte FD, Nogaro GP, Martins DS, Kunz M, et al. The effect of antipsychotics on the cognitive performance of individuals with psychotic disorders: Network meta-analyses of randomized controlled trials. Neurosci Biobehav Rev 2021; 126:265-275.
5. Gao K, Goto T, Yuan C, Brownrigg B, Conroy C, Chan PK, et al. A pilot study of the effectiveness of lithium versus quetiapine immediate release monotherapy in patients with bipolar spectrum disorders. J Clin Psychopharmacol 2018; 38:422-434.
6. Scott J, Etain B, Bellivier F. Can an integrated science approach to precision medicine research improve lithium treatment in bipolar disorders? Front Psychiatry 2018; 9:1-10.
7. Severus E, Taylor MJ, Sauer C, Pfennig A, Ritter P, Bauer M, et al. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. Int J Bipolar Disord 2014; 2:1-17.
8. Malhi GS, Adams D, Berk M. Is lithium in a class of its own? A brief profile of its clinical use. Aust N Z J Psychiatry 2009; 43:1096-1104.
9. Pachet AK, Wisniewski AM. The effects of lithium on cognition: An updated review. Psychopharmacology 2003; 170:225-234.
10. Wingo AP, Wingo TS, Harvey PD, Baldessarini RJ. Effects of lithium on cognitive performance: A meta-analysis. J Clin Psychiatry 2009; 70:1588-1597.
11. Amiri S, Jafari-Sabet M, Keyhanfar F, Falak R, Shabani M, Rezayof A. Hippocampal and prefrontal cortical NMDA receptors mediate the interactive effects of olanzapine and lithium in memory retention in rats: the involvement of CAMKII-CREB signaling pathways. Psychopharmacology 2020; 237:1383-1396.
12. Parsaei L, Torkaman-Boutorabi A, Asadi F, Zarrindast M-R. Interaction between dorsal hippocampal NMDA receptors and lithium on spatial learning consolidation in rats. Brain Res Bull 2016; 127:1-10.
13. Ghasemi M, Dehpour AR. The NMDA receptor/nitric oxide pathway: A target for the therapeutic and toxic effects of lithium. Trends Pharmacol Sci 2011; 32:420-434.
14. Purdon SE, Malla A, Labelle A, Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci 2001; 26:137.
15. Velligan DI, Newcomer J, Pultz J, Csernansky J, Hoff AL, Mahurin R, et al. Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr Res 2002; 53:239-248.
16. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018; 20:97-170.
17. Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006; 20:389-409.
18. Kasper S, Resinger E. Cognitive effects and antipsychotic treatment. Psychoneuroendocrinology 2003; 28:27-38.
19. Yan B, Bi X, He J, Zhang Y, Thakur S, Xu H, et al. Quetiapine attenuates spatial memory impairment and hippocampal neurodegeneration induced by bilateral common carotid artery occlusion in mice. Life Sci 2007; 81:353-361.
20. Pira L, Mongeau R, Pani L. The atypical antipsychotic quetiapine increases both noradrenaline and dopamine release in the rat prefrontal cortex. Eur J Pharmacol 2004; 504:61-64.
21. Tarazi FI, Baldessarini RJ, Kula NS, Zhang K. Long-term effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: implications for antipsychotic drug treatment. J Pharmacol Exp Ther 2003; 306:1145-1151.
22. Jafari-Sabet M. NMDA receptor blockers prevents the facilitatory effects of post-training intra-dorsal hippocampal NMDA and physostigmine on memory retention of passive avoidance learning in rats. Behav Brain Res 2006; 169:120-127.
23. Jafari-Sabet M, Khodadadnejad M-A, Ghoraba S, Ataee R. Nitric oxide in the dorsal hippocampal area is involved on muscimol state-dependent memory in the step-down passive avoidance test. Pharmacol Biochem Behav 2014; 117:137-143.
24. Jafari-Sabet M, Banafshe HR, Khodadadnejad M-A. Modulation of muscimol state-dependent memory by α2-adrenoceptors of the dorsal hippocampal area. Eur J Pharmacol 2013; 710:92-99.
25. Izquierdo I, Bevilaqua LR, Rossato JI, Bonini JS, Medina JH, Cammarota M. Different molecular cascades in different sites of the brain control memory consolidation. Trends Neurosci 2006; 29:496-505.
26. Lisman J, Schulman H, Cline H. The molecular basis of CaMKII function in synaptic and behavioural memory. Nat Rev Neurosci 2002; 3:175.
27. Nelson T, Ur C, Gruol D. Chronic intermittent ethanol exposure enhances NMDA-receptor-mediated synaptic responses and NMDA receptor expression in hippocampal CA1 region. Brain Res 2005; 1048:69-79.
28. Goodwin Go, Psychopharmacology CGotBAf. Evidence-based guidelines for treating bipolar disorder: revised second edition—recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009; 23:346-388.
29. Ketter TA, Miller S, Dell’Osso B, Wang PW. Treatment of bipolar disorder: Review of evidence regarding quetiapine and lithium. J Affect Disord 2016; 191:256-273.
30. Jafari-Sabet M, Amiri S, Ataee R. Cross state-dependency of learning between tramadol and MK-801 in the mouse dorsal hippocampus: involvement of nitric oxide (NO) signaling pathway. Psychopharmacology 2018; 235:1987-1999.
31. Hammonds MD, Shim SS. Effects of 4‐week treatment with lithium and olanzapine on levels of brain‐derived neurotrophic factor, B‐cell CLL/lymphoma 2 and phosphorylated cyclic adenosine monophosphate response element‐binding protein in the sub‐regions of the hippocampus. Basic Clin Pharmacol Toxicol 2009; 105:113-119.
32. He J, Liu F, Zu Q, Xu Z, Zheng H, Li X, et al. Chronic administration of quetiapine attenuates the phencyclidine-induced recognition memory impairment and hippocampal oxidative stress in rats. NeuroReport 2018; 29:1099-1103.
33. Mutlu A, Mutlu O, Ulak G, Akar F, Kaya H, Erden F, et al. Superior effects of quetiapine compared with aripiprazole and iloperidone on MK-801-induced olfactory memory impairment in female mice. Biomed Rep 2017; 6:567-570.
34. Paxinos G, Watson C. The rat brain in stereotaxic coordinates in stereotaxic coordinates: Elsevier; 2007.
35. Senturk V, Goker C, Bilgic A, Olmez S, Tugcu H, Oncu B, et al. Impaired verbal memory and otherwise spared cognition in remitted bipolar patients on monotherapy with lithium or valproate. Bipolar Disord 2007; 9:136-144.
36. Zarrindast MR, Parsaei L, Ahmadi S. Repeated administration of histamine improves memory retrieval of inhibitory avoidance by lithium in mice. Pharmacology 2008; 81:187-194.
37. Böer U, Cierny I, Krause D, Heinrich A, Lin H, Mayr G, et al. Chronic lithium salt treatment reduces CRE/CREB-directed gene transcription and reverses its upregulation by chronic psychosocial stress in transgenic reporter gene mice. Neuropsychopharmacology 2008; 33:2407.
38. Rantamäki T, Knuuttila JE, Hokkanen M-E, Castrén E. The effects of acute and long-term lithium treatments on trkB neurotrophin receptor activation in the mouse hippocampus and anterior cingulate cortex. Neuropharmacology 2006; 50:421-427.
39. Shim SS, Hammonds MD, Tatsuoka C, Feng IJ. Effects of 4-weeks of treatment with lithium and olanzapine on long-term potentiation in hippocampal area CA1. Neurosci Lett 2012; 524:5-9.
40. Tsaltas E, Kontis D, Boulougouris V, Papakosta V-M, Giannou H, Poulopoulou C, et al. Enhancing effects of chronic lithium on memory in the rat. Behav Brain Res 2007; 177:51-60.
41. Potvin S, Stip E, Roy J-Y. Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses. Int Clin Psychopharmacol 2003; 18:121-132.
42. Martin MV, Dong H, Bertchume A, Csernansky JG. Low dose quetiapine reverses deficits in contextual and cued fear conditioning in rats with excitotoxin-induced hippocampal neuropathy. Pharmacol Biochem Behav 2005; 82:263-269.
43. Tempier A, He J, Zhu S, Zhang R, Kong L, Tan Q, et al. Quetiapine modulates conditioned anxiety and alternation behavior in Alzheimer’s transgenic mice. Curr Alzheimer Res 2013; 10:199-206.
44. He J, Zu Q, Wen C, Liu Q, You P, Li X, et al. Quetiapine Attenuates Schizophrenia-Like Behaviors and Demyelination in a MK-801–Induced Mouse Model of Schizophrenia. Front Psychiatry 2020:843.
45. Poddar I, Callahan PM, Hernandez CM, Pillai A, Yang X, Bartlett MG, et al. Oral quetiapine treatment results in time-dependent alterations of recognition memory and brain-derived neurotrophic factor-related signaling molecules in the hippocampus of rats. Pharmacol Biochem Behav 2020; 197:172999.
46. Bourin MS, Severus E, Schronen JP, Gass P, Szamosi J, Eriksson H, et al. Lithium as add-on to quetiapine XR in adult patients with acute mania: A 6-week, multicenter, double-blind, randomized, placebo-controlled study. Int J Bipolar Disord 2014; 2:1-11.
47. Denys D, Klompmakers AA, Westenberg HG. Synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine. Psychopharmacology 2004; 176:195-203.
48. He J, Xu H, Yang Y, Rajakumar D, Li X, Li X-M. The effects of chronic administration of quetiapine on the phencyclidine-induced reference memory impairment and decrease of Bcl-XL/Bax ratio in the posterior cingulate cortex in rats. Behav Brain Res 2006; 168:236-242.
49. Tanibuchi Y, Fujita Y, Kohno M, Ishima T, Takatsu Y, Iyo M, et al. Effects of quetiapine on phencyclidine-induced cognitive deficits in mice: A possible role of α1-adrenoceptors. Eur Neuropsychopharmacol 2009; 19:861-867.
50. Warburton EC, Barker GR, Brown MW. Investigations into the involvement of NMDA mechanisms in recognition memory. Neuropharmacology 2013; 74:41-47.
51. de Lima MNM, Laranja DC, Bromberg E, Roesler R, Schröder N. Pre-or post-training administration of the NMDA receptor blocker MK-801 impairs object recognition memory in rats. Behav Brain Res 2005; 156:139-143.
52. Jafari-Sabet M, Mofidi H, Attarian-Khosroshahi MS. NMDA receptors in the dorsal hippocampal area are involved in tramadol state-dependent memory of passive avoidance learning in mice. Can J Physiol Pharmacol 2017; 96:45-50.
53. Cammarota M, Bevilaqua LR, Ardenghi P, Paratcha G, de Stein ML, Izquierdo I, et al. Learning-associated activation of nuclear MAPK, CREB and Elk-1, along with Fos production, in the rat hippocampus after a one-trial avoidance learning: abolition by NMDA receptor blockade. Brain Res Mol Brain Res 2000; 76:36-46.
54. Yamamura S, Ohoyama K, Hamaguchi T, Kashimoto K, Nakagawa M, Kanehara S, et al. Effects of quetiapine on monoamine, GABA, and glutamate release in rat prefrontal cortex. Psychopharmacology 2009; 206:243-258.
55. Fumagalli F, Molteni R, Bedogni F, Gennarelli M, Perez J, Racagni G, et al. Quetiapine regulates FGF-2 and BDNF expression in the hippocampus of animals treated with MK-801. Neuroreport 2004; 15:2109-2112.